Patient-powered adjunctive
treatment for MDD
symptoms1

Empower your patients with information and support options throughout the 6-week
treatment period.

MDD=major depressive disorder.

Is Rejoyn right for your patients?

As an adjunct to ADT, Rejoyn may be a suitable option for adults age 22+ with MDD who1:

  • Still want improvement in their MDD symptoms
  • Are motivated to do more to treat their MDD symptoms1
  • Are interested in a different type of adjunctive MDD treatment1

In the clinical trial, adding Rejoyn reduced MDD symptoms in patients who reported an inadequate response to their current ADT.1

ADT=antidepressant therapy.

Talking to patients about Rejoyn

If your patients want to add to their ADT for MDD, consider Rejoyn.1 More information is available on the patient site.1

Here are some key points to keep in mind when discussing Rejoyn as an option:

Zero with a line through it to represent zero adverse events related to Rejoyn

Zero side effects related to Rejoyn

In a clinical trial, participants didn’t experience side effects related to treatment with Rejoyn.1

Icon of a mobile phone with an Rx in it representing that Rejoyn is a prescription app

The first prescription app for MDD symptoms

Rejoyn works differently than medication. It’s a prescription app that’s been authorized by the FDA as an add-on treatment for MDD symptoms in adults age 22+.1,2

Icon showing x6 on a calendar to represent 6 weeks of treatment

6-week commitment

Rejoyn consists of cognitive-emotional training (CET) exercises and cognitive behavioral therapy (CBT)-based video lessons. The CET brain exercises and CBT-based video lessons are each done 3 times a week, for only 6 weeks.1

Icon of a brain with two dots that are connected

Like physical therapy for the brain

The exercises in Rejoyn are designed to be challenging because they're helping push the brain to build stronger connections.1,2

Three arrows that are trending down representing a reduction in MDD symptoms

Reduced MDD symptoms

In a clinical trial, Rejoyn was shown to reduce MDD symptoms when added to ADT.1

Icon of a chat bubble with three dots representing the text messages sent by Rejoyn

Support for your patient's treatment

Rejoyn sends daily motivating text messages to help patients stay on top of exercises and lessons.

Icon of a person representing patient privacy

Protecting patient privacy

Privacy guardrails are in place to ensure patient data remains safe and protected while using Rejoyn.

Icon of a person with a medical symbol

End-to-end nurse support

A dedicated team of nurses will proactively reach out to your patients and provide them with support throughout their treatment with Rejoyn. Patients must opt in to receive this service.

Built-in patient support

The Rejoyn app is designed to help patients feel supported at every point in their treatment, and offers:

  • Icon of a chat bubble with three dots representing the text messages sent by Rejoyn
    Automatic engagement text messages and therapeutic in-app notifications
  • Icon of a person with a medical symbol
    End-to-end nurse support throughout the 6-week treatment program when patients opt in through the app and agree to share data about their treatment
  • Icon of a phone
    A knowledgeable support team that can be reached at 1-833-Y-REJOYN (1-833-973-5696) Monday through Friday, 8 AM to 8 PM ET, excluding holidays

Ways for you to support

your patients

  • Icon of a flag
    Help patients commit: Consider your patient’s schedule. Given the 6-week commitment, patients may want to avoid starting at times when they are making any big changes (eg, taking a trip or starting a new job)1
  • Icon of upwards trending bars ending in an accomplishment ribbon
    Encourage patients to do as much as they can: It's important for patients to stick with treatment. See the adherence rate in a clinical trial1
  • Icon of a person with a medical symbol
    Advise patients to opt in for end-to-end nurse support: Patients can opt in through the app at any time and a dedicated team of nurses will reach out directly to them to check in during their treatment with Rejoyn
  • Icon of a hand holding a person, symbolizing healthcare provider support for patients
    Encourage patients to talk about their experience: At each visit, ask patients about their progress with Rejoyn and the impact it is having on their MDD symptoms
Woman sitting on a chair looking at her smartphone using the Rejoyn app
Woman sitting on a chair looking at her smartphone using the Rejoyn app

We’re here to help

If you or your patients have questions or need help, support is available. Please call 1-833-Y-REJOYN (1-833-973-5696) Monday through Friday, 8 AM to 8 PM ET, excluding holidays.

Where to find Rejoyn

App Store
Google Play

INDICATION: Rejoyn is a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. It is intended to reduce MDD symptoms.

SAFETY INFORMATION: Rejoyn is not intended to be used as a standalone therapy or a substitute for medication. Patients should continue their current treatment as directed.

Rejoyn does not monitor the patient's symptoms or clinical status and cannot send or receive alerts or warnings to the prescriber. Patients should be clearly instructed that if they believe their depression is worsening or if they have feelings or thoughts of harming themselves or others, to contact a healthcare professional, dial 911 or go to the nearest emergency room immediately.

The Apple logo is a trademark of Apple Inc., registered in the United States and other countries. App Store is a service mark of Apple Inc., registered in the United States and other countries. Google Play and the Google Play logo are trademarks of Google LLC.